Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.50
+$0.40 · +3.31%
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Previous close
$12.50
+$0.40 · +3.31%
After-hours
$12.50
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Day range
Current $12.50
52-week range
Current $12.50
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
55
Fair Value
Sentiment
57
Mixed
Risk
53
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Day range
Current $12.50
52-week range
Current $12.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65.32M USD | 67.64M USD | 79.2M USD | 86.16M USD | 97.07M USD |
| Cost of goods sold | 4.59M USD | — | — | — | — |
| Gross profit | 60.74M USD | 67.64M USD | 79.2M USD | 86.16M USD | 97.07M USD |
| Research and development | 106.74M USD | 131.48M USD | 163.52M USD | 164.52M USD | 174.11M USD |
| Selling, general, and administrative | 43.93M USD | 57.85M USD | 52.89M USD | 45.48M USD | 32.54M USD |
| Operating expenses | 146.09M USD | 189.33M USD | 216.41M USD | 210M USD | 206.65M USD |
| Interest income | 9.48M USD | 14.77M USD | 11.36M USD | 1.57M USD | 2.02M USD |
| Interest expense | 7.68M USD | 10.94M USD | 5.15M USD | — | — |
| Depreciation and amortization | 5.09M USD | 2.34M USD | 2.37M USD | 2.97M USD | 3.33M USD |
| Operating income | −85.35M USD | −121.69M USD | −137.21M USD | −123.84M USD | −109.57M USD |
| Net income | −81.89M USD | −116.05M USD | −133.82M USD | −121.76M USD | −79M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
60.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI11.69M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM9.1M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF4.18M0.00%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB2.59M0.02%10.28B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO2.18M0.01%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1.64M0.01%21.73B USD0.03%$32.79+0.40%
Dimensional - US Small Cap ETFDFAS1.58M0.00%33.87B USD0.31%$78.35+0.32%
iShares Russell 2000 Growth ETFIWO1.56M0.01%13.97B USD0.24%$356.78+0.94%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
